Università di Parma
TECMED Lab
Experimental and Applied Medical Technologies Lab

NanoKos: Increase Research Capacities in Kosovo. Nanoparticles in Environment and Medical Research. EuropeAID BGUE-B2020-22.020102-C1-NEAR DELKOS.  2023-2025.


The project funded by EU  focus on the investigation of inhalable nanoparticles from environmental and medical research with the final aim to implement research capacites in Kosovo. Student and postdoc from University of Pristina will join our Lab, King's College and University of Milan for their formation based on this sharing project on cardiovascular disease and (nano) therapies for strengthening the collaboration among groups. Starting month March 2023


Novel Nanomaterials for cardiovascular nanomedicine: SPOKE 1, Materials for sustainability and ecological transition. WP4: Advanced materials and devices for health industry, diagnostics and therapeutics with a one-Health approach. Source of Funding : PNRR : Next Generation EU: 2022-2025

The first subproject aims to develop and test nanomaterials for cardiovascular nanomedicine: in details we are producing and testing Silicon Carbide Conductive Nanowires capable to synthetically reinstate impulse propagaiton in the heart (please see our recent Nature Communications article). In this project we aim to approach SiC-NWs for terminating sustained arrhythmias.

The second subproject aims to develop  nanoparticles capable to release pharmaceutical compounds after  inhalation at the pulmonary and cardiovascular level and after application at ocular level. A patent is pending for the administration procedure of the nanoparticles. This project adopt 3D biopriting for developing materials capable to local release pharmacological compounds.


AVATHEEART: Dissecting the Role of Impairment in Contractility in Hypoplastic Left Heart Syndrome by Organoids on a chip Technology.  Source of Funding : FIL-UNIPR 2024-2026

In this project we are providing cardiac organoids derived fro, iPSc directly from patients undergoing Glenn and Fontan Procedures in HLHS syndrome. WE will focus on the contractility impairment and drug screening in the context of personalized medicine by transferring our results in the clinical setting of patients undergoing the aforementioned procedure. We will take advantage of our Loki platform and the Vi.Ki.E technology  within the operating rooms, collaborating with University of Verona and CNR.

PAST GRANTS


New method for assessing cardiac contraction parameters for the in-vivo beating cardiac tissue: The Project LVAD-STRAT ERAPERMED  2019-2022


We are developing, in collaboration with the Bio engineer Department and Mathematical Department at University of Pavia, and the University of Verona a new method for studying kinematic evaluation of cardiac contraction (ViKiE) at high spatial and temporal resolutions. The ViKiE computer vision technology is part of the new European Project on Personalized Medicine ERAPERMED that aims to acquire right ventricular performance in patients during Left ventricular assistant device implantation.

The  system works in a different way as compared to the commercial ones: briefly, we are recording, in a contact-less fashion manner, the cardiac beating cycle from a beating syncytium, ranging from a single sarcomere of the cardiomyocyte to the entire heart with a high-speed bright-field camera for 1-5 sec. From the video file, a customized algorithm follows the trajectories of a given location during contraction/relaxation processes and returns Hamiltonian mechanical equations such as force, contraction velocity, kinetic energy and displacement. In clinics, VikiE works in parallel with trans-esophageal ecocardiografy during open-chest cardiac surgery and return, in real-time, prognostics and diagnostic values to the surgeons. LVAD-STRAT


New method for predict arrhythmia in Obstructive sleep Apnea Patients: The project SLEEP@SA 2019-2022

SLEEP@SA is a funded project from BRIC INAIL where our team are entitle to develop an Artificial Intelligence able to  predict the worsening of cardiac dysfunction in OSA patients. In details we will acquire from worker (pilots, drivers that have a unbalanced biorhythm)  ECG, BP and stress biomarkers. All acquired and analyzed data will feed a machine learning for developing such prediction more information at SLEEPOSAS webiste .

Nanoparticles and cardiac drug delivery: targeting the disease heart via respiratory pathway. The Project CUPIDO 2017-2021

This is indeed, the other side of the coin, i.e. developing nanoparticles able to carry and deliver specific drugs to the failing heart (such as microRNAs or specific peptides). This is possible with manipulation of the physicochemical nanoparticle characteristics. The goal of this subproject, conducted in collaboration with the Department of Life Science University of Parma, IRGB-CNR and ISTEC-CNR, joint partners in the European Project Cupido, is to obtain a deeper understating of the possibility to use electrically charged nanoparticles (promising results are obtained with calcium phosphate nanoparticles) for carrying drugs specifically to the failing heart. more details at: www.cupidoproject.eu






FUNDING AGENCIES

 GA 720834  LVADSTRAT
Federottica.org | Inail: obblighi e responsabilità del datore di lavoro Il Piano Nazionale di Ripresa e Resilienza (PNRR ...